Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -404K | -378K | 0 | 0 |
| Operating Income | -26M | -54M | -9M | -953K | -5M |
| EBITDA | -26M | -13M | -59M | 4M | -15M |
| Net Income | -26M | -10M | -60M | 4M | -16M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$9.46
-2.47% today
1Y Change
-81.95%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tevogen Bio Holdings Inc. (TVGN) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $9.46 and down 81.9% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -72.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -72.6%, free cash flow -3.3% with operating margin 0.0% and ROIC 3698.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TVGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TVGN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TVGN Max Drawdown
-93.19%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TVGN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$15.6M
-453.8% YoY
Free Cash Flow
-$5.4M
+41.1% YoY
Revenue Growth
+0.0%
EPS Growth
-72.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -404K | -378K | 0 | 0 |
| Operating Income | -26M | -54M | -9M | -953K | -5M |
| EBITDA | -26M | -13M | -59M | 4M | -15M |
| Net Income | -26M | -10M | -60M | 4M | -16M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 552K | 1M | 1M | 5M | 7M |
| Total Assets | 4M | 3M | 6M | 8M | 8M |
| Total Liabilities | 13M | 10M | 100M | 42M | 24M |
| Shareholder Equity | -8M | -7M | -94M | -34M | -16M |
| Total Debt | 3M | 3M | 95M | 40M | 23M |
| Net Debt | 3M | 2M | 94M | 35M | 16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
+39.1% YoY
Capital Expenditures
110K
+77.1% YoY
Free Cash Flow
5M
+41.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
316.0%
Debt / Equity
-0.38x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.